section name header

Information

[Section Outline]

Rocky Mountain Spotted Fever (Rmsf) !!navigator!!

Epidemiology !!navigator!!

Caused by R. rickettsii, RMSF has the highest case-fatality rate of all rickettsial diseases.

  • In the United States, the prevalence is highest in the south-central and southeastern states. Most cases occur between May and September.
  • A rare presentation of fulminant RMSF is seen most often in male black pts with G6PD deficiency.
  • RMSF is transmitted by different ticks in different geographic areas-e.g., the American dog tick (Dermacentor variabilis) transmits RMSF in the eastern two-thirds of the United States and in California, and the Rocky Mountain wood tick (D. andersoni) transmits RMSF in the western United States.

Pathogenesis !!navigator!!

Rickettsiae are inoculated by the tick after 6 h of feeding, spread lymphohematogenously, and infect numerous foci of contiguous endothelial cells. Increased vascular permeability, with edema, hypovolemia, and ischemia, causes tissue and organ injury.

Clinical Manifestations !!navigator!!

The incubation period is 1 week (range, 2-14 days). After 3 days of nonspecific symptoms, half of pts have a rash characterized by macules appearing on the wrists and ankles and subsequently spreading to the rest of the extremities and the trunk.

  • Lesions ultimately become petechial in 41-59% of pts, appearing on or after day 6 of illness in 74% of all cases that include a rash. The palms and soles become involved after day 5 in 43% of pts but do not become involved at all in 18-64%.
  • Pts may develop hypovolemia, prerenal azotemia, hypotension, noncardiogenic pulmonary edema, renal failure, hepatic injury, and cardiac involvement with dysrhythmias. Bleeding is a rare but potentially life-threatening consequence of severe vascular damage.
  • CNS involvement-manifesting as encephalitis, focal neurologic deficits, or meningoencephalitis-is an important determinant of outcome. In meningoencephalitis, CSF findings are notable for pleocytosis with a mononuclear-cell or neutrophil predominance, increased protein levels, and normal glucose levels.
  • Laboratory findings may include increased plasma levels of acute-phase reactants such as C-reactive protein, hypoalbuminemia, hyponatremia, and elevated levels of creatine kinase.

Prognosis !!navigator!!

Without treatment, the pt usually dies in 8-15 days; fulminant RMSF can result in death within 5 days. The mortality rate is 3-5% despite the availability of effective antibiotics, mostly because of delayed diagnosis. Survivors of RMSF usually return to their previous state of health.

Diagnosis !!navigator!!

Within the first 3 days, diagnosis is difficult, since only 3% of pts have the classic triad of fever, rash, and known history of tick exposure. When the rash appears, RMSF should be considered.

  • Immunohistologic examination of a cutaneous biopsy sample from a rash lesion is the only useful diagnostic test during acute illness, with a sensitivity of 70% and a specificity of 100%.
  • Serology, most commonly the indirect immunofluorescence assay, is usually positive 7-10 days after disease onset, and a diagnostic titer of 1:64 is usually documented.
TREATMENT

Rocky Mountain Spotted Fever

  • Doxycycline (100 mg bid PO or IV) is the agent of choice for both children and adults but not for pregnant women and pts allergic to this drug, who should receive chloramphenicol.
  • Treatment is given until the pt is afebrile and has been improving (usually 3-5 days after defervescence).

Other Tick-Borne Spotted Fevers !!navigator!!

  • R. conorii causes disease in southern Europe, Africa, and Asia. The name for R. conorii infection varies by region (e.g., Mediterranean spotted fever, Kenya tick typhus).
    • Disease is characterized by high fever, rash, and-in most locales-an inoculation eschar (tâche noire) at the site of the tick bite that appears before the onset of fever.
    • A severe form of disease with a mortality rate of 50% occurs in pts with diabetes, alcoholism, or heart failure.
  • R. africae causes African tick-bite fever, which occurs in sub-Saharan Africa and the Caribbean and is a mild illness consisting of headache, fever, eschar, and regional lymphadenopathy.
  • Tick-borne spotted fever is diagnosed on the basis of clinical and epidemiologic findings; the diagnosis is confirmed by serology or detection of rickettsiae.
TREATMENT

Other Tick-Borne Spotted Fevers

Doxycycline (100 mg PO bid for 1-5 days) or chloramphenicol (500 mg qid PO for 7-10 days) is effective for treatment. Pregnant pts may be treated with josamycin (3 g/d PO for 5 days).

Rickettsialpox !!navigator!!

Epidemiology

Rickettsialpox is caused by R. akari and is maintained by mice and their mites. Recognized principally in New York City, rickettsialpox has been reported in other urban and rural locations in the United States as well as in Ukraine, Croatia, Mexico, and Turkey.

Clinical Manifestations

A papule forms at the site of the mite bite and develops a central vesicle that becomes a painless black-crusted eschar surrounded by an erythematous halo. Lymph nodes draining the region of the eschar enlarge.

  • After an incubation period of 10-17 days, malaise, chills, fever, headache, and myalgia mark disease onset.
  • A macular rash appears on day 2-6 of illness and evolves sequentially into papules, vesicles, and crusts that heal without scarring.
  • If untreated, fever lasts 6-10 days.
TREATMENT

Rickettsialpox

Doxycycline is the drug of choice for treatment.

Outline

Section 7. Infectious Diseases